Skip to main
BBNX

BBNX Stock Forecast & Price Target

BBNX Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 33%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Beta Bionics has demonstrated significant financial growth, with Q3'25 revenue reaching $27.3 million, reflecting a 63.3% year-over-year increase, and notable outperformance against expectations by $3.8 million. The company has revised its revenue forecasts for 2025 and 2026 upward to $97.5 million and $136 million, respectively, bolstered by strong new patient starts, particularly from the pharmacy channel which contributes higher-margin sales. Additionally, the expansion of the insulin pump market through successful conversions of multiple daily injection patients and the increase in sales territories from 43 to 63 further supports a robust outlook for sustained top-line growth in the coming years.

Bears say

Beta Bionics Inc faces several fundamental risks that contribute to a negative outlook for its stock. The company may struggle to achieve significant market share with its iLet product launch amid competitive pressures and complicated pharmacy penetration, which could lead to downward revisions of revenue and profitability estimates. Additionally, challenges in regulatory approvals, potential capital needs resulting in shareholder dilution, and unfavorable changes in Medicare reimbursement frameworks could further hinder the company's financial stability and growth prospects.

BBNX has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 33% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Beta Bionics Inc (BBNX) Forecast

Analysts have given BBNX a Buy based on their latest research and market trends.

According to 9 analysts, BBNX has a Buy consensus rating as of Dec 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Beta Bionics Inc (BBNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.